{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tubal+Carcinoma", "query": { "condition": "Tubal Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tubal+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-25T00:38:43.334Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00050375", "title": "Clinical Trial for Ovarian Cancer (OvaRex®)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "oregovomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Unither Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 354, "start_date": "2002-12", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2007-12-18", "last_synced_at": "2026-07-25T00:38:43.334Z", "location_count": 62, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "La Verne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00050375" }, { "nct_id": "NCT00181688", "title": "Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Carcinoma", "Tubal Carcinoma" ], "interventions": [ { "name": "Iressa (ZD1839)", "type": "DRUG" }, { "name": "Arimidex (Anastrozole)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 35, "start_date": "2003-10", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2012-12-05", "last_synced_at": "2026-07-25T00:38:43.334Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00181688" }, { "nct_id": "NCT05463796", "title": "InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer Risk", "Cancer Predisposition Syndrome", "Hereditary Cancer Prediction", "Childhood Cancer Survivors", "Adult Cancer Survivors", "IARC Carcinogens", "Smoking History", "Lung Cancer", "Ductal/Lobular Carcinoma", "Barrett Esophagus", "Pancreatic Precursor Lesions", "Colonic Dysplasia/Adenomata", "Non-Alcoholic Fatty Liver Disease", "Non Alcoholic Steatohepatitis", "Cirrhosis", "High Grade Prostatic Epithelial Neoplasia", "High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ", "Adenomatous Hyperplasia", "High-risk Oral Precancerous Diseases", "Melanocytic Lesion, Adult", "Hematologic Malignancy", "Lung; Node", "Serous Tubal Intraepithelial Carcinoma", "Endometrial Intraepithelial Neoplasia", "Cervical and Endocervical Carcinoma in Situ", "Vulvar Intraepithelial Neoplasia", "Nephrogenic Rests", "Benign Bone Lesions With Risk of Malignant Degeneration", "Giant Cell Tumor", "Osteochondroma", "Spitz Nevus" ], "interventions": [ { "name": "Samples", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5000, "start_date": "2023-04-25", "completion_date": "2032-03-25", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-07-25T00:38:43.334Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05463796" }, { "nct_id": "NCT00003634", "title": "Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "oregovomab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AltaRex", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 400, "start_date": "1998-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-07-25T00:38:43.334Z", "location_count": 29, "location_summary": "Berkeley, California • Los Angeles, California • Orange, California + 25 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pomona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003634" }, { "nct_id": "NCT03593681", "title": "Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Ovarian Neoplasms", "Ovary Cancer", "Fallopian Tube Neoplasms", "Fallopian Tube Adenocarcinoma", "High Grade Serous Carcinoma", "Peritoneal Carcinoma", "Peritoneal Neoplasms", "Adnexal Mass", "Ovarian Diseases" ], "interventions": [ { "name": "Hysteroscopic cell sampling of the fallopian tube", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 150, "start_date": "2018-08-27", "completion_date": "2020-02-14", "has_results": true, "last_update_posted_date": "2021-01-20", "last_synced_at": "2026-07-25T00:38:43.334Z", "location_count": 10, "location_summary": "San Diego, California • San Francisco, California • Jacksonville, Florida + 7 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03593681" }, { "nct_id": "NCT00003380", "title": "Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "etoposide", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": null, "start_date": "1998-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-10", "last_synced_at": "2026-07-25T00:38:43.334Z", "location_count": 62, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003380" }, { "nct_id": "NCT00352300", "title": "Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Carcinoma", "Infectious Disorder", "Neutropenia", "Ovarian Carcinosarcoma", "Primary Peritoneal Carcinoma", "Stage III Ovarian Cancer", "Stage IV Ovarian Cancer" ], "interventions": [ { "name": "Adjuvant Therapy", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 43, "start_date": "2006-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-12-31", "last_synced_at": "2026-07-25T00:38:43.334Z", "location_count": 11, "location_summary": "Orange, California • Iowa City, Iowa • Camden, New Jersey + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Camden", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00352300" }, { "nct_id": "NCT00003385", "title": "Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 48, "start_date": "1999-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-07-25T00:38:43.334Z", "location_count": 7, "location_summary": "Honolulu, Hawaii • Iowa City, Iowa • Bethesda, Maryland + 3 more", "locations": [ { "city": "Honolulu", "state": "Hawaii" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003385" }, { "nct_id": "NCT00004060", "title": "Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "exatecan mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "1999-07", "completion_date": "2000-09", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-07-25T00:38:43.334Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004060" }, { "nct_id": "NCT00003334", "title": "Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Sarcoma" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "FEMALE", "summary": "Up to 120 Years · Female only" }, "enrollment_count": null, "start_date": "1997-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-03-11", "last_synced_at": "2026-07-25T00:38:43.334Z", "location_count": 5, "location_summary": "New York, New York • The Bronx, New York • Valhalla, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003334" } ] }